Zurcher Kantonalbank Zurich Cantonalbank Grows Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Zurcher Kantonalbank Zurich Cantonalbank lifted its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 34.5% in the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 100,603 shares of the medical research company's stock after acquiring an additional 25,778 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank owned 0.06% of IQVIA worth $23,840,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in IQV. Versant Capital Management Inc increased its position in IQVIA by 733.3% during the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company's stock valued at $26,000 after acquiring an additional 110 shares during the last quarter. Opal Wealth Advisors LLC acquired a new position in shares of IQVIA in the 2nd quarter valued at $27,000. Capital Performance Advisors LLP acquired a new stake in IQVIA during the 3rd quarter worth approximately $27,000. Park Place Capital Corp purchased a new position in IQVIA in the third quarter valued at approximately $28,000. Finally, Itau Unibanco Holding S.A. purchased a new position in shares of IQVIA in the 2nd quarter valued at approximately $29,000. Institutional investors own 89.62% of the company's stock.

IQVIA Price Performance

IQV stock traded down $0.59 during mid-day trading on Friday, hitting $200.84. 513,717 shares of the stock were exchanged, compared to its average volume of 1,174,636. The business has a fifty day moving average price of $218.67 and a 200 day moving average price of $226.20. IQVIA Holdings Inc. has a 12 month low of $187.62 and a 12 month high of $261.73. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The stock has a market capitalization of $36.45 billion, a price-to-earnings ratio of 26.37, a PEG ratio of 2.07 and a beta of 1.51.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on IQV shares. Evercore ISI dropped their target price on IQVIA from $270.00 to $265.00 and set an "outperform" rating on the stock in a report on Tuesday, October 8th. StockNews.com lowered IQVIA from a "buy" rating to a "hold" rating in a report on Thursday. TD Cowen cut their price target on IQVIA from $270.00 to $255.00 and set a "buy" rating on the stock in a research note on Friday, November 1st. BTIG Research lowered their target price on IQVIA from $290.00 to $260.00 and set a "buy" rating on the stock in a research report on Friday, November 1st. Finally, Leerink Partners reissued an "outperform" rating and issued a $248.00 target price (down from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Five equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $256.50.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.